Literature DB >> 17451192

Practical guidelines for the treatment of inflammatory bowel disease.

T Kuhbacher, U R Fölsch.   

Abstract

In recent years, great progress has been made regarding the treatment of inflammatory bowel disease (IBD), particularly in the field of biological therapies. Nevertheless, the ultimate treatment is not in sight. With the development of new medication, it has become clear that we need a new understanding of IBD. Therapy needs to fit the different subtypes of IBD; e.g. mild disease in comparison to severe chronic active disease or Crohn's disease with or without fistulation or stenosis. The following article gives a practical overview of actual treatments for IBD. The intention of this article is not to provide a complete review of all new scientific developments, but to give a practical guideline for therapy of IBD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451192      PMCID: PMC4146986          DOI: 10.3748/wjg.v13.i8.1149

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  90 in total

Review 1.  The state of the art in the management of inflammatory bowel disease.

Authors:  Stephen B Hanauer; Daniel H Present
Journal:  Rev Gastroenterol Disord       Date:  2003

2.  Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

Authors:  R Löfberg; P Rutgeerts; H Malchow; C Lamers; A Danielsson; G Olaison; D Jewell; O Ostergaard Thomsen; H Lorenz-Meyer; H Goebell; H Hodgson; T Persson; C Seidegård
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

3.  Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.

Authors:  A B Hawthorne; R F Logan; C J Hawkey; P N Foster; A T Axon; E T Swarbrick; B B Scott; J E Lennard-Jones
Journal:  BMJ       Date:  1992-07-04

4.  Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.

Authors:  Danial E Baker
Journal:  Rev Gastroenterol Disord       Date:  2004

5.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

Review 6.  New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.

Authors:  William J Sandborn
Journal:  Rev Gastroenterol Disord       Date:  2005

7.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

8.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

9.  Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.

Authors:  Stephen B Hanauer; Burton I Korelitz; Paul Rutgeerts; Mark A Peppercorn; Ronald A Thisted; Russell D Cohen; Daniel H Present
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

10.  Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome.

Authors:  M Mogadam; W O Dobbins; B I Korelitz; S W Ahmed
Journal:  Gastroenterology       Date:  1981-01       Impact factor: 22.682

View more
  10 in total

1.  Association between TNF-alpha and Entamoeba histolytica diarrhea.

Authors:  Kristine M Peterson; Jianfen Shu; Priya Duggal; Rashidul Haque; Dinesh Mondal; William A Petri
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

Review 2.  Therapeutic potential of helminths in autoimmune diseases: helminth-derived immune-regulators and immune balance.

Authors:  Meng Wang; Linxiang Wu; Rennan Weng; Weihong Zheng; Zhongdao Wu; Zhiyue Lv
Journal:  Parasitol Res       Date:  2017-06-29       Impact factor: 2.289

3.  TGF-beta1 gene-modified, immature dendritic cells delay the development of inflammatory bowel disease by inducing CD4(+)Foxp3(+) regulatory T cells.

Authors:  Zhijian Cai; Wei Zhang; Min Li; Yinpu Yue; Fei Yang; Lei Yu; Xuetao Cao; Jianli Wang
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

4.  Quality of care for patients with inflammatory bowel disease in East China.

Authors:  Qin Zhu; Qian Cao; Jian-Min Si
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

5.  Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study.

Authors:  Sinyoung Park; Yang Hee Noh; Sun Young Rha; Won Ho Kim; Jae Hee Cheon
Journal:  Intest Res       Date:  2015-06-09

6.  Validation and optimization of experimental colitis induction in rats using 2, 4, 6-trinitrobenzene sulfonic acid.

Authors:  A Motavallian-Naeini; S Andalib; M Rabbani; P Mahzouni; M Afsharipour; M Minaiyan
Journal:  Res Pharm Sci       Date:  2012-07

Review 7.  Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease.

Authors:  Rebeca Martín; Sylvie Miquel; Jonathan Ulmer; Noura Kechaou; Philippe Langella; Luis G Bermúdez-Humarán
Journal:  Microb Cell Fact       Date:  2013-07-23       Impact factor: 5.328

8.  Breast-feeding protects infantile diarrhea caused by intestinal protozoan infections.

Authors:  Ekhlas Hamed Abdel-Hafeez; Usama Salah Belal; Manal Zaki Mohamed Abdellatif; Koji Naoi; Kazumi Norose
Journal:  Korean J Parasitol       Date:  2013-10-31       Impact factor: 1.341

9.  A platform of genetically engineered bacteria as vehicles for localized delivery of therapeutics: Toward applications for Crohn's disease.

Authors:  Ryan McKay; Monil Ghodasra; John Schardt; David Quan; Alex Eli Pottash; Wu Shang; Steven M Jay; Gregory F Payne; Matthew Wook Chang; John C March; William E Bentley
Journal:  Bioeng Transl Med       Date:  2018-09-23

10.  Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease.

Authors:  Todd Atherly; Giacomo Rossi; Robin White; Yeon-Jung Seo; Chong Wang; Mark Ackermann; Mary Breuer; Karin Allenspach; Jonathan P Mochel; Albert E Jergens
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.